Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Impedimed Limited ( (AU:IPD) ) just unveiled an update.
Impedimed Limited has announced the cessation of 13,642,113 options, designated as IPDAAB, which were set to expire on various dates at various exercise prices. These securities lapsed on 31 March 2026 after the conditional rights attached to them were not satisfied or became incapable of being met, resulting in a reduction of the company’s outstanding options and a modest simplification of its capital structure for shareholders.
The notification, lodged as a new announcement on 13 April 2026, confirms that the change affects only conditional options rather than ordinary shares on issue. While the move does not directly raise or return capital, it may marginally reduce potential future dilution for existing investors and clarify the company’s pool of exercisable equity instruments going forward.
The most recent analyst rating on (AU:IPD) stock is a Buy with a A$0.05 price target. To see the full list of analyst forecasts on Impedimed Limited stock, see the AU:IPD Stock Forecast page.
More about Impedimed Limited
Impedimed Limited is an Australian-listed company on the ASX under the code IPD. The firm operates in the medical technology sector, though this notice focuses on its capital structure rather than its products or specific market segments.
YTD Price Performance: -55.88%
Average Trading Volume: 6,812,612
Technical Sentiment Signal: Sell
Current Market Cap: A$30.58M
For detailed information about IPD stock, go to TipRanks’ Stock Analysis page.